A Study of Overgrowth in Small Intestine Bacteria from Long Term Use of Medication Limiting Stomach Acid

Overview

About this study

The purpose of this study is to find out if taking long term medication to limit stomach acid results in the overgrowth of small intestine bacteria

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Age18-75 years
Able to provide consent
Endoscopically documented esophagitis or newly diagnosed Barrett’s Esophagus
Starting PPI therapy for at least 12 months (must be free of PPI use within the past year)

Exclusion Criteria

Non-fluent in English
Non-US residents
Institutionalized or incarcerated
Has a legal guardian
Current, recent (within 1 week) or recurrent antibiotic therapy
Diabetics or other individuals in whom glucose administration would be contraindicated
Past Small Intestine Bacterial Overgrowth
History of altered small intestinal anatomy (e.g. Roux en Y anatomy) that would affect ability to detect SIBO via GBT

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Conor Loftus, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Conor Loftus, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials